Hyperprolactinemia Associated with Drugs
At a Glance
Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary unit. In premenopausal women, hyperprolactinemia causes hypogonadism, leading to symptoms of infertility, oligomenorrhea or amenorrhea, and galactorrhea. Hyperprolactinemia is often clinically silent in postmenopausal women who, by definition, are already hypogonadal. In men, hyperprolactinemia causes hypogonadism manifested by decreased libido, impotence, infertility, and, rarely, galactorrhea.
Several drugs are known to cause minimal to moderate hyperprolactinemia:
Selective serotonin reuptake inhibitors
H2-receptor blocking agents
Opiates and Opiate Antagonists
These should be ruled-out as potential causes of hyperprolactinemia prior to investigating organic causes.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
Measurement of serum prolactin is necessary to identify hyperprolactinemia. Testing can be performed without regard to time of day, because routine daily activities have little influence on prolactin concentration.
Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?
Prolactin concentrations slightly greater than the reference interval should be confirmed by repeat testing on a new blood sample, because prolactin may be influenced by strenuous exercise, emotional or physical stress, or rigorous stimulation of breast tissue.
Macroprolactin is a complex of prolactin and IgG and is a source of hyperprolactinemia in some individuals. Because of its high molecular mass, macroprolactin has prolonged clearance that can cause an apparent hyperprolactinemia. In the absence of clinical symptoms, hyperprolactinemia due to macroprolactin can cause clinical confusion. It is important to be aware that macroprolactinemia can coexist with true hyperprolactinemia.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL